Pharmaceutical biology industry: vaccine industry is now inflection point to pay attention to plate opportunities

Vaccine potential varieties have been listed, the industry opened up room for development
before the domestic vaccine sector is not valued by the market, because most of the varieties are low-cost one type of seedlings and homogenization of serious second-class seedlings, fierce competition, limited corporate profits. At present, the vaccine industry is in the stage of potential varieties market and release, AC-Hib triple vaccine and EV71 hand, foot and mouth disease vaccine in the rapid growth period after the market, imported 2 price and 4 price HPV vaccine after 10 years of waiting has been approved, domestic 13 price pneumonia vaccine and HPV vaccine on the eve of the market, the industry is at an upward inflection point.Vaccine industry concentration is high, is the pharmaceutical sector in the sub-blue sea
According to the data of the China National Inspection Institute, there are currently about 35 domestic vaccine batch issued enterprises, and there are more heavy product research and development enterprises, the market is very concentrated; For the country's huge health population, especially young children, so the vaccine industry is more sensitive, imported products will be subject to certain restrictions, the current national first-class seedlings only procurement of domestic products, in 2016 the total amount of imported vaccine issuance accounted for only 2.3%, domestic enterprises competition pattern is good. And from the product registration situation, vaccine oligarch competition, for the domestic large number of healthy people, is the real blue sea in the field of medicine.Vaccine industry is preferential by policy, subject to tenders and medical insurance restrictions less
vaccine industry bidding system and drugs are not the same, because of their own varieties are less, new products can be dynamically added after the market, not limited by the progress of bidding, the speed of release. And the second type of vaccine does not occupy the funds of health insurance, by the people to choose their own vaccination, so the vaccine has been high-quality and excellent price, will not be limited by the cost of health insurance. In addition, prevention is more economical than treatment, and the CDC reports that $1 vaccine spending saves about $5-27 in treatment costs, so vaccines are strongly supported by the state and have preferential policies.
second-class vaccine has the attribute of consumer goods, but also benefit from the consumption upgrade of the second-class vaccine people choose to vaccinate, is a medical product with consumption attribute. China is in the most significant stage of consumption escalation, vaccines as the most effective means of preventing disease, there will be a high degree of acceptance. At present, in China's consumer goods industry, "upgrade" is a very important investment idea in the market, in the field of medical consumption, mainly reflected in the upgrading of rigid drugs, as well as the rise of non-rigid high-end medical needs, vaccines belong to this category. With the spread of emerging media, public awareness will change more rapidly, and vaccination rates are expected to increase as payment levels increase.Investment Recommendations
Vaccines to see new varieties, limited growth of old products, new product launches will bring performance growth to enterprises, so we focus on potential varieties of vaccine companies: Watson Bio (13 price pneumonia combined vaccine and 2 price HPV vaccine to be listed), Kantai Bio (MRC-5 rabies vaccine to be listed, in the research potential variety), Zhifei Bio (AC-Hib vaccine release, agent Mersa East 4 price HPV on the market).risk
risk of product development failure, product promotion is not as expected, and the impact of vaccine industry events. (China Net)